Neuroscience
An FDA press release:
FOR IMMEDIATE RELEASE
P06-211
December 20, 2006
Media Inquiries: Karen Riley, 301-827-6242
Consumer Inquiries: 888-INFO-FDA
FDA Approves Novel Device That Prevents or Reduces Brain Damage in Infants
The Food and Drug Administration (FDA) today approved a first-of-a-kind medical device for the treatment of babies born with moderate to severe hypoxic-ischemic encephalopathy (HIE), a potentially fatal injury to the brain caused by low levels of oxygen. The Olympic Cool-Cap system is designed to prevent or reduce damage to the brains of these patients by keeping the head cool while the body is maintained at a slightly below-normal temperature. The Cool-Cap is manufactured by Olympic Medical Corporation, a subsidiary of Natus Medical Incorporated of San Carlos, Calif.
“This approval brings new hope to parents of the approximately 5,000-9,000 babies each year who are born in the United States with moderate to severe hypoxic-ischemic encephalopathy,” said Dr. Daniel Schultz, director of FDA’s Center for Devices and Radiological Health. “Until now, there has been no effective treatment for these infants other than supportive care. Up to 20 percent of them died, and 25 percent suffered permanent disability because of neurological deficits.”
The Olympic Cool-Cap treats the patient by maintaining a steady flow of water at a selected cool temperature through a cap covering the infant’s head. The system, which consists of a cooling unit, a control unit, temperature probes and a water-filled cap, was found safe and effective in a study with 234 infants with moderate to severe HIE. At 18 months of age, there were fewer deaths and fewer severe cases of neurodevelopmental disability in the cooled group compared with the control group.
As conditions of the approval, Olympic Medical Corporation will set up a patient registry to collect information on device usage and to track treatment outcomes; organize a training and certification process for all operators of the device; and restrict use of the device to patients who meet the eligibility criteria defined by the original study.
- Fda: Lundbeck's Sabril (vigabatrin) And Infantile Spasms
From a press release by the FDA: Sabril Approved by FDA to Treat Spasms in Infants and Epileptic Seizures Sabril (vigabatrin) Oral Solution has been approved by the U.S. Food and Drug Administration to treat infantile spasms in children ages 1 month to...
- Fda Approves Invega (paliperidone)
An FDA Press Release: FOR IMMEDIATE RELEASE P06-208 December 20, 2006 Media Inquiries: Press Office, 301-827-6242 Consumer Inquiries: 888-INFO-FDA FDA Approves New Drug for Schizophrenia The Food and Drug Administration (FDA) today approved Invega (paliperidone)...
- Business World: Boston Scientific, Wingspan Stent System, & Stroke
From the Boston Business Journal website:Boston Scientific stent system gains limited approval Boston Business Journal 11:16 AM EDT Tuesday Boston Scientific Corp. has gotten limited regulatory approval for a stent system to treat a stroke. The Natick,...
- Business World: Cyberonics, Neurostimulator (vagus Nerve Stimulator [vns]), And Depression
News about this controversial issue (See the list at the bottom of this posting for earlier BrainBlog posts.) From the company's press release:FDA APPROVES CYBERONICS’ VNS THERAPY™ SYSTEM FOR TREATMENT-RESISTANT DEPRESSION (TRD) First FDA-Approved...
- Upcoming Event: Gaithersburg, Md, 17 June 2005
From the FDA: NEUROLOGICAL DEVICES PANEL OF THE MEDICAL DEVICES ADVISORY COMMITTEE (FDA) DATE AND TIME: June 17, 8:30 a.m. LOCATION: Hilton Washington, DC North/Gaithersburg, Salons A, B and C, 620 Perry Pkwy., Gaithersburg, MD. CONTACT: Janet L. Scudiero,...
Neuroscience
FDA Approves Cool-Cap
An FDA press release:
FOR IMMEDIATE RELEASE
P06-211
December 20, 2006
Media Inquiries: Karen Riley, 301-827-6242
Consumer Inquiries: 888-INFO-FDA
FDA Approves Novel Device That Prevents or Reduces Brain Damage in Infants
The Food and Drug Administration (FDA) today approved a first-of-a-kind medical device for the treatment of babies born with moderate to severe hypoxic-ischemic encephalopathy (HIE), a potentially fatal injury to the brain caused by low levels of oxygen. The Olympic Cool-Cap system is designed to prevent or reduce damage to the brains of these patients by keeping the head cool while the body is maintained at a slightly below-normal temperature. The Cool-Cap is manufactured by Olympic Medical Corporation, a subsidiary of Natus Medical Incorporated of San Carlos, Calif.
“This approval brings new hope to parents of the approximately 5,000-9,000 babies each year who are born in the United States with moderate to severe hypoxic-ischemic encephalopathy,” said Dr. Daniel Schultz, director of FDA’s Center for Devices and Radiological Health. “Until now, there has been no effective treatment for these infants other than supportive care. Up to 20 percent of them died, and 25 percent suffered permanent disability because of neurological deficits.”
The Olympic Cool-Cap treats the patient by maintaining a steady flow of water at a selected cool temperature through a cap covering the infant’s head. The system, which consists of a cooling unit, a control unit, temperature probes and a water-filled cap, was found safe and effective in a study with 234 infants with moderate to severe HIE. At 18 months of age, there were fewer deaths and fewer severe cases of neurodevelopmental disability in the cooled group compared with the control group.
As conditions of the approval, Olympic Medical Corporation will set up a patient registry to collect information on device usage and to track treatment outcomes; organize a training and certification process for all operators of the device; and restrict use of the device to patients who meet the eligibility criteria defined by the original study.
- Fda: Lundbeck's Sabril (vigabatrin) And Infantile Spasms
From a press release by the FDA: Sabril Approved by FDA to Treat Spasms in Infants and Epileptic Seizures Sabril (vigabatrin) Oral Solution has been approved by the U.S. Food and Drug Administration to treat infantile spasms in children ages 1 month to...
- Fda Approves Invega (paliperidone)
An FDA Press Release: FOR IMMEDIATE RELEASE P06-208 December 20, 2006 Media Inquiries: Press Office, 301-827-6242 Consumer Inquiries: 888-INFO-FDA FDA Approves New Drug for Schizophrenia The Food and Drug Administration (FDA) today approved Invega (paliperidone)...
- Business World: Boston Scientific, Wingspan Stent System, & Stroke
From the Boston Business Journal website:Boston Scientific stent system gains limited approval Boston Business Journal 11:16 AM EDT Tuesday Boston Scientific Corp. has gotten limited regulatory approval for a stent system to treat a stroke. The Natick,...
- Business World: Cyberonics, Neurostimulator (vagus Nerve Stimulator [vns]), And Depression
News about this controversial issue (See the list at the bottom of this posting for earlier BrainBlog posts.) From the company's press release:FDA APPROVES CYBERONICS’ VNS THERAPY™ SYSTEM FOR TREATMENT-RESISTANT DEPRESSION (TRD) First FDA-Approved...
- Upcoming Event: Gaithersburg, Md, 17 June 2005
From the FDA: NEUROLOGICAL DEVICES PANEL OF THE MEDICAL DEVICES ADVISORY COMMITTEE (FDA) DATE AND TIME: June 17, 8:30 a.m. LOCATION: Hilton Washington, DC North/Gaithersburg, Salons A, B and C, 620 Perry Pkwy., Gaithersburg, MD. CONTACT: Janet L. Scudiero,...